黛力新治疗肠易激综合征的临床观察

【目的】观察黛力新对肠易激综合征（IBS）的疗效及其抗抑郁的作用,探索如何提高肠易激综合征的治疗效果。【方法】80例IBS患者,均符合罗马Ⅲ标准,随机分为治疗组和对照组,每组40例。对照组给予曲美布汀、适怡治疗;治疗组在对照组的基础上加用黛力新治疗,两组疗程均为4周,治疗期间均停用其他药物。观察两组患者的治疗总有效率及单项症状疗效;并测定两组患者治疗前后汉密尔顿抑郁量表（HAMD）得分,进行比较判定。【结果】治疗组总有效率为95％,对照组总有效率为75％,差异有显著性（P〈0．05）;黛力新治疗组治疗腹痛、腹胀、腹泻总有效率高于对照组,差异有显著性（P〈0．05）;经4周治疗后治疗组HAMD得分明显低于对照组,两组比较差异显著性（P〈0．05）。【结论】黛力新更能明显改善IBS患者抑郁症状,增加疗效,值得进一步推广。

Clinical Efficacy of Deanxit in the Treatment of Irritable Bowel Syndrome

[Objective]To observe the clinical efficacy of deanxit in the treatment of irritable bowel syndrome （IBS）. [Methods] Eighty patients of IBS were all fit for RomeⅢ. They were divided into experimental group and control group randomly with 40 patients in each group. The patients in the experimental group took deanxit two times daily, trimebutine maleate capsules 0. 2 three times daily and oral Laosuansuojun Tanghuajun Changqiujun Huojunzhiji three times daily. The patients in control group took trimebutane capsules 0.2 three times daily and oral Laosuansuojun Tanghuajun Changqiujun Huojunzhiji three times daily, and the courses of treatment were 4 weeks. The other kinds of drugs were stopped in the treatment period. [Results] The overall efficacy of the experimental group was 95%, and the control group was 75%, and the significant difference was found between the two groups（ P〈0.05）. The experimental group were different from the control group in the symptoms of abdominal pain, abdominal distension and diarrhea （ P〈0.05）. The scores of HAMD decreased in both groups, and there was significant difference between two groups （ P d0.05）. The scores of HAMD in experimental group were obviously lower than those in control group. [Conclusion] Deanxit can further decrease the scores of HAMD in patients with IBS. Deanxit has good therapeutic effect for IBS.